Zeng D - Search Results

1

Magic year for multiple myeloma therapeutics: Key takeaways from the ASH 2015 annual meeting.

Zhang K, Desai A, Zeng D, Gong T, Lu P, Wang M. Zhang K, et al. Among authors: zeng d. Oncotarget. 2017 Feb 7;8(6):10748-10759. doi: 10.18632/oncotarget.13314. Oncotarget. 2017. PMID: 27863374 Free PMC article. Review.

2

Smoldering mantle cell lymphoma.

Ye H, Desai A, Zeng D, Nomie K, Romaguera J, Ahmed M, Wang ML. Ye H, et al. Among authors: zeng d. J Exp Clin Cancer Res. 2017 Dec 15;36(1):185. doi: 10.1186/s13046-017-0652-8. J Exp Clin Cancer Res. 2017. PMID: 29246179 Free PMC article. Review.

3

Challenges and Opportunities for High-grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangement (Double-hit Lymphoma).

Zeng D, Desai A, Yan F, Gong T, Ye H, Ahmed M, Nomie K, Romaguera J, Champlin R, Li S, Wang M. Zeng D, et al. Am J Clin Oncol. 2019 Mar;42(3):304-316. doi: 10.1097/COC.0000000000000427. Am J Clin Oncol. 2019. PMID: 29419530 Review.

4

The CD20-specific engineered toxin antibody MT-3724 exhibits lethal effects against mantle cell lymphoma.

Huang S, Jiang C, Zhang H, Bell T, Guo H, Liu Y, Yao Y, Zeng D, Ahmed M, Nomie K, Zhang L, Wang M. Huang S, et al. Among authors: zeng d. Blood Cancer J. 2018 Mar 20;8(3):33. doi: 10.1038/s41408-018-0066-7. Blood Cancer J. 2018. PMID: 29559616 Free PMC article. No abstract available.

5

Spontaneous regression of mantle cell lymphoma: a report of four cases.

Ye H, Desai A, Gong T, Zeng D, Nomie K, Chen W, Wang W, Romaguera J, Wang ML. Ye H, et al. Among authors: zeng d. Cancer Commun (Lond). 2018 May 29;38(1):30. doi: 10.1186/s40880-018-0306-z. Cancer Commun (Lond). 2018. PMID: 29843782 Free PMC article.

6

Frontline Treatment for Older Patients with Mantle Cell Lymphoma.

Ye H, Desai A, Zeng D, Romaguera J, Wang ML. Ye H, et al. Among authors: zeng d. Oncologist. 2018 Nov;23(11):1337-1348. doi: 10.1634/theoncologist.2017-0470. Epub 2018 Jun 12. Oncologist. 2018. PMID: 29895632 Free PMC article. Review.

7

Paramount therapy for young and fit patients with mantle cell lymphoma: strategies for front-line therapy.

Ye H, Desai A, Huang S, Jung D, Champlin R, Zeng D, Yan F, Nomie K, Romaguera J, Ahmed M, Wang ML. Ye H, et al. Among authors: zeng d. J Exp Clin Cancer Res. 2018 Jul 13;37(1):150. doi: 10.1186/s13046-018-0800-9. J Exp Clin Cancer Res. 2018. PMID: 30005678 Free PMC article. Review.

8

Long-term outcomes and mutation profiling of patients with mantle cell lymphoma (MCL) who discontinued ibrutinib.

Jain P, Kanagal-Shamanna R, Zhang S, Ahmed M, Ghorab A, Zhang L, Ok CY, Li S, Hagemeister F, Zeng D, Gong T, Chen W, Badillo M, Nomie K, Fayad L, Medeiros LJ, Neelapu S, Fowler N, Romaguera J, Champlin R, Wang L, Wang ML. Jain P, et al. Among authors: zeng d. Br J Haematol. 2018 Nov;183(4):578-587. doi: 10.1111/bjh.15567. Epub 2018 Sep 2. Br J Haematol. 2018. PMID: 30175400 Free article.

9

Dual inhibition of PI3K signaling and histone deacetylation halts proliferation and induces lethality in mantle cell lymphoma.

Guo H, Zeng D, Zhang H, Bell T, Yao J, Liu Y, Huang S, Li CJ, Lorence E, Zhou S, Gong T, Jiang C, Ahmed M, Yao Y, Nomie KJ, Zhang L, Wang M. Guo H, et al. Among authors: zeng d. Oncogene. 2019 Mar;38(11):1802-1814. doi: 10.1038/s41388-018-0550-3. Epub 2018 Oct 25. Oncogene. 2019. PMID: 30361685

10

Erratum.

[No authors listed] [No authors listed] Int J Cancer. 2023 Sep 15;153(6):E4-E5. doi: 10.1002/ijc.34619. Epub 2023 Jun 6. Int J Cancer. 2023. PMID: 37278120 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

2,973 results

Search Page

Filters